GH Research (GHRS) Stock Price, News & Analysis

Company Overview

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Key Stats

• Today's Range: $9.64 to $10.63
• 50-Day Range: $6.85 to $10.60
• 52-Week Range: $6.00 to $14.99
• Volume: 170,976 shs
• Average Volume: 92,087 shs
• Market Capitalization: $551.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.67
• Consensus Rating: Buy

GH Research Stock Analysis - MarketRank™

GH Research scored higher than 39% of companies evaluated by MarketBeat, and ranked 753rd out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

GH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

GH Research has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GH Research are expected to decrease in the coming year, from ($0.80) to ($1.13) per share.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.92% of the float of GH Research has been sold short.

Short Interest Ratio / Days to Cover

GH Research has a short interest ratio ("days to cover") of 33.1, which indicates bearish sentiment.

Change versus previous month

Short interest in GH Research has recently increased by 5.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GH Research does not currently pay a dividend.

Dividend Growth

GH Research does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.92% of the float of GH Research has been sold short.

Short Interest Ratio / Days to Cover

GH Research has a short interest ratio ("days to cover") of 33.1, which indicates bearish sentiment.

Change versus previous month

Short interest in GH Research has recently increased by 5.70%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.37

News Sentiment

GH Research has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for GH Research this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for GHRS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

3 people have added GH Research to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GH Research insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GHRS Stock Analysis - Frequently Asked Questions

How have GHRS shares performed this year?

GH Research's stock was trading at $7.00 at the beginning of the year. Since then, GHRS stock has increased by 51.4% and is now trading at $10.60.
View the best growth stocks for 2025 here.

How were GH Research's earnings last quarter?

GH Research PLC (NASDAQ:GHRS) issued its earnings results on Tuesday, September, 3rd. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03.

When did GH Research IPO?

GH Research (GHRS) raised $150 million in an IPO on Friday, June 25th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of GH Research?

Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GH Research own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GH Research investors own include Baidu (BIDU), Shopify (SHOP), Bristol-Myers Squibb (BMY), Zoom Video Communications (ZM), Atai Life Sciences (ATAI), CRISPR Therapeutics (CRSP) and Caesars Entertainment (CZR).

Company Calendar

• Last Earnings: 9/03/2024
• Today: 2/01/2025
• Next Earnings (Estimated): 3/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GHRS
• CUSIP: N/A
• CIK: 1855129
• Web: www.ghres.com
• Phone: 212-450-4000
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $35.67
• High Stock Price Target: $40.00
• Low Stock Price Target: $28.00
• Potential Upside/Downside: +236.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,590,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.29%
• Return on Assets: -19.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.83
• Quick Ratio: 15.83

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 52,030,000
• Free Float: 30,384,000
• Market Cap: $551.52 million
• Optionable: Optionable
• Beta: 0.84